I agree with you VuBru. If I remember correctly LP said the dcvax-l trial has been designed with various subtypes analysis. And we already know based on data presented the vaccine is highly correlated to certain subtype. This data speaks louder. This is a gift for longs here. If longs can’t appreciate it and still depressed due to price per share, I don’t know what to say. Use price to your own advantage. IMO.